Ischemic Stroke Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Ischemic Stroke therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Ischemic Stroke Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Ischemic Stroke Market.

The Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Ischemic Stroke Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Ischemic Stroke and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Ischemic Stroke market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More About the Evolving Therapeutic Dynamics @ Ischemic Stroke Therapeutics Assessment

Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates

Route of Administration
Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
– Inhalation
– Inhalation/Intravenous/Oral
– Intranasal
– Intravenous
– Intravenous/ Subcutaneous
– Oral
– Oral/intranasal/subcutaneous
– Parenteral
– Subcutaneous

Molecule Type
Products have been categorized under various Molecule types, such as
– Antibody
– Antisense oligonucleotides
– Immunotherapy
– Monoclonal antibody
– Peptides
– Protein
– Recombinant protein
– Small molecule
– Stem Cell
– Vaccine

Mechanism of Action of the Emerging Pipeline Therapies
– NMDA receptor antagonist
– Plasminogen activator
– RGMA protein inhibitor
– Virus replication inhibitor
– Platelet membrane glycoprotein VI inhibitor
– CD4-positive T lymphocyte stimulant
– Immunomodulator
– Activated protein C receptor modulator

Ischemic Stroke Therapeutics Landscape

There are approx. 50+ key companies which are developing therapies for Ischemic Stroke. Currently, Athersys, Inc. is leading the therapeutics market with its Ischemic Stroke drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Ischemic Stroke Therapeutics Market include:
Acticor Biotech, Algernon Pharmaceuticals, aptaTargets, Athersys, Inc., Avilex Pharma, Biogen, Bristol-Myers Squibb, DiaMedica Therapeutics Inc, Ever Supreme Bio Technology Co., Ltd., Genentech, Inc., GNT Pharma, GrandPharma (China) Co., Ltd., Guangzhou Recomgen Biotech Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., Lumosa Therapeutics, Meridigen Biotech Co., Ltd., Nanjing Yoko Biomedical Co., Ltd., NC Medial Research Inc, Ninnion, NoNO Inc., NuvOX Pharma, Pharming Technologies B.V., Prolong Pharmaceuticals, Revalesio, Roche, SanBio, Shin Poong Pharmaceutical, StemCyte, Stemedica Cell Technologies, Suzhou Yabao Pharmaceutical R&D Co., Ltd., Tarveda Therapeutics, Teijin Pharma Limited, TrueBinding, Inc., ZZ Biotech, and many others.

Ischemic Stroke Therapies covered in the report include:
– 3K3A-APC: ZZ Biotech
– ApTOLL: aptaTargets
– BIIB131 (TMS-007): Biogen
– Elezanumab: Tarveda Therapeutics
– LT3001: Lumosa Therapeutics
– Microlyse: TargED Biopharmaceuticals
– MultiStem: Athersys, Inc.
– RNS60: Revalesio Corporation
And many more

Explore More About the Emerging Drugs and Key Companies @ Ischemic Stroke Pipeline Development Activities

Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Ischemic Stroke Current Treatment Patterns
4. Ischemic Stroke – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Ischemic Stroke Late-Stage Products (Phase-III)
7. Ischemic Stroke Mid-Stage Products (Phase-II)
8. Ischemic Stroke Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Ischemic Stroke Discontinued Products
13. Ischemic Stroke Product Profiles
14. Key Companies in the Ischemic Stroke Market
15. Key Products in the Ischemic Stroke Therapeutics Segment
16. Dormant and Discontinued Products
17. Ischemic Stroke Unmet Needs
18. Ischemic Stroke Future Perspectives
19. Ischemic Stroke Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Get a Detailed Assessment of the Ongoing Clinical and Regulatory Development Activities @ Ischemic Stroke Therapeutic Outlook

Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.